These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22116203)

  • 1. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation.
    Capobianco M; Motuzova Y; Frau J; Cocco E; Mamusa E; Marrosu MG; Bertolotto A
    Neurol Sci; 2012 Aug; 33(4):863-7. PubMed ID: 22116203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
    Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
    Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
    Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
    Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis.
    O'Connor P
    Expert Opin Biol Ther; 2007 Jan; 7(1):123-36. PubMed ID: 17150024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab.
    Berger JR
    Drugs Today (Barc); 2006 Oct; 42(10):639-55. PubMed ID: 17136224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    Kalincik T; Sharmin S; Roos I; Massey J; Sutton I; Withers B; Freedman MS; Atkins H; Krasulova E; Kubala Havrdova E; Trneny M; Kozak T; Burman J; Macdonell R; Torkildsen Ø; Bø L; Lehmann AK; Sharrack B; Snowden J
    J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):775-783. PubMed ID: 38538060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
    Burman J; Fransson M; Tötterman TH; Fagius J; Mangsbo SM; Loskog AS
    Immunology; 2013 Oct; 140(2):211-9. PubMed ID: 23721329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
    Prosperini L; De Angelis F; De Angelis R; Fanelli F; Pozzilli C
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):236-8. PubMed ID: 24790213
    [No Abstract]   [Full Text] [Related]  

  • 13. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D; Giovannoni G
    Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Natalizumab: an antibody targeting α4-integrin].
    Nakahara J
    Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.